|
1
|
Kannel WB: Fifty years of framingham study
contributions to understanding hypertension. J Hum Hypertens.
14:83–90. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Baena CP, Olandoski M, Younge JO,
Buitrago-Lopez A, Darweesh SK, Campos N, Sedaghat S, Sajjad A, van
Herpt TT, Freak-Poli R, et al: Effects of lifestyle-related
interventions on blood pressure in low and middle-income countries:
Systematic review and meta-analysis. J Hypertens. 32:961–973. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dickinson HO, Mason JM, Nicolson DJ,
Campbell F, Beyer FR, Cook JV, Williams B and Ford GA: Lifestyle
interventions to reduce raised blood pressure: A systematic review
of randomized controlled trials. J Hypertens. 24:215–233. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lifton RP, Gharavi AG and Geller DS:
Molecular mechanisms of human hypertension. Cell. 104:545–556.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Timberlake DS, O'Connor DT and Parmer RJ:
Molecular genetics of essential hypertension: Recent results and
emerging strategies. Curr Opin Nephrol Hypertens. 10:71–79. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Singh M, Mensah GA and Bakris G:
Pathogenesis and clinical physiology of hypertension. Cardiol Clin.
28:545–559. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Szmitko PE and Verma S: Cardiology patient
pages. Red wine and your heart. Circulation. 111:e10–e11. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Duffy SJ and Vita JA: Effects of phenolics
on vascular endothelial function. Curr Opin Lipidol. 14:21–27.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ferrières J: The French paradox: Lessons
for other countries. Heart. 90:107–111. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kopp P: Resveratrol, a phytoestrogen found
in red wine. A possible explanation for the conundrum of the
‘French paradox’? Eur J Endocrinol. 138:619–620. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fremont L: Biological effects of
resveratrol. Life Sci. 66:663–673. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
EFSA Panel on Dietetic Products, Nutrition
and Allergies (NDA), . Safety of synthetic trans-resveratrol as a
novel food pursuant to Regulation (EC) No 258/97. EFSA J.
14:43682016. View Article : Google Scholar
|
|
13
|
Dolinsky VW, Chan AY, Frayne I Robillard,
Light PE, Des Rosiers C and Dyck JR: Resveratrol prevents the
prohypertrophic effects of oxidative stress on LKB1. Circulation.
119:1643–1652. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cao X, Luo T, Luo X and Tang Z:
Resveratrol prevents AngII-induced hypertension via AMPK activation
and RhoA/ROCK suppression in mice. Hypertens Res. 37:803–810. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kearney PM, Whelton M, Reynolds K, Muntner
P, Whelton PK and He J: Global burden of hypertension: Analysis of
worldwide data. Lancet. 365:217–223. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
World Health Organization. A global brief
on hypertension, . Silent killer, global public health crises
(World Health Day 2013). Geneva: WHO;
|
|
17
|
The World health statistics 2012 report.
Geneva: WHO;
|
|
18
|
Kearney PM, Whelton M, Reynolds K, Whelton
PK and He J: Worldwide prevalence of hypertension: A systematic
review. J Hypertens. 22:11–19. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wolf-Maier K, Cooper RS, Kramer H, Banegas
JR, Giampaoli S, Joffres MR, Poulter N, Primatesta P, Stegmayr B
and Thamm M: Hypertension treatment and control in five European
countries, Canada, and the United States. Hypertension. 43:10–17.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kuneš J, Kadlecová M, Vaněčková I and
Zicha J: Critical developmental periods in the pathogenesis of
hypertension. Physiol Res. 61:(Suppl 1). S9–S17. 2012.PubMed/NCBI
|
|
21
|
Kunes J and Zicha J: The interaction of
genetic and environmental factors in the etiology of hypertension.
Physiol Res. 58:(Suppl 2). S33–S41. 2009.PubMed/NCBI
|
|
22
|
Widlansky ME, Gokce N, Keaney JF Jr and
Vita JA: The clinical implications of endothelial dysfunction. J Am
Coll Cardiol. 42:1149–1160. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rajendran P, Rengarajan T, Thangavel J,
Nishigaki Y, Sakthisekaran D, Sethi G and Nishigaki I: The vascular
endothelium and human diseases. Int J Biol Sci. 9:1057–1069. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Klatz R and Goldman R: A4M American
academy of anti-aging medicine. Anti-Aging Therapeutics.
XVI:Chapter 11. 2015.
|
|
25
|
Tousoulis D, Kampoli AM, Tentolouris C,
Papageorgiou N and Stefanadis C: The role of nitric oxide on
endothelial function. Curr Vasc Pharmacol. 10:4–18. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Furchgott RF and Zawadzki J: The
obligatory role of endothelial cells in the relaxation of arterial
smooth muscle by acetylcholine. Nature. 288:373–376. 1980.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ignarro LJ, Byrns RE and Wood KS:
Biochemical and pharmacological properties of endothelium-derived
relaxing factor and its similarity to nitric oxide
radicalVasodilatation: Vascular smooth muscle peptides, autonomic
nerves and endothelium. Vanhoutte P.M.: Raven Press; New York: pp.
427–436. 1988
|
|
28
|
Furchgott RF and Vanhoutte PM:
Endothelium-derived relaxing and contracting factors. FASEB J.
3:2007–2018. 1989.PubMed/NCBI
|
|
29
|
SoRelle R: Nobel prize awarded to
scientists for nitric oxide discoveries. Circulation. 98:2365–2366.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hermann M, Flammer A and Lüscher TF:
Nitric oxide in hypertension. J Clin Hypertens (Greenwich). 8:(12
Suppl 4). S17–S29. 2006. View Article : Google Scholar
|
|
31
|
Endemann DH and Schiffrin EL: Endothelial
dysfunction. J Am Soc Nephrol. 15:1983–1992. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
de la Sierra A and Larrousse M:
Endothelial dysfunction is associated with increased levels of
biomarkers in essential hypertension. J Hum Hypertens. 24:373–379.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dolinsky VW, Morton JS, Oka T,
Robillard-Frayne I, Bagdan M, Lopaschuk GD, Des Rosiers C, Walsh K,
Davidge ST and Dyck JR: Calorie restriction prevents hypertension
and cardiac hypertrophy in the spontaneously hypertensive rat.
Hypertension. 56:412–421. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dolinsky VW, Chakrabarti S, Pereira TJ,
Oka T, Levasseur J, Beker D, Zordoky BN, Morton JS, Nagendran J,
Lopaschuk GD, et al: Resveratrol prevents hypertension and cardiac
hypertrophy in hypertensive rats and mice. Biochim Biophys Acta.
1832:1723–1733. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen ZP, Mitchelhill KI, Michell BJ,
Stapleton D, Rodriguez-Crespo I, Witters LA, Power DA, de
Montellano PR Ortiz and Kemp BE: AMP-activated protein kinase
phosphorylation of endothelial NO synthase. FEBS Lett. 443:285–289.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang J, Xie Z, Dong Y, Wang S, Liu C and
Zou MH: Identification of nitric oxide as an endogenous activator
of the AMP-activated protein kinase in vascular endothelial cells.
J Biol Chem. 283:27452–27461. 2008. View Article : Google Scholar : PubMed/NCBI
|
